Webinar
Clinical Trial Considerations in Neurodegenerative Disease

Clinical Trial Considerations in Neurodegenerative Disease Webinar

April 10, 2019

4:00 pm ET

1:00 pm PT

 

Online

Running clinical trials for neurodegenerative disease can be challenging, due to the complexity of studies, rapidly evolving knowledge of disease areas, regulatory considerations, obstacles facing patient recruitment, and difficulties in patient retention.

Drawing from her extensive experience in managing clinical trials in Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple other neurological disorders, Dr. Tina Soulis of Neuroscience Trials Australia will share best practices and helpful tips for moving clinical stage research forward.

You'll Learn:

  • Unique considerations for running clinical trials for neurodegeneration-related diseases, including choosing biomarkers, study design, and data management
  • Advantages of running clinical trials in Australia
  • How to optimize patient recruitment and retention specifically for neurodegenerative diseases

About the Speaker

Tina Soulis, PhD, is the CEO of Neuroscience Trials Australia. She is considered an industry thought leader and Australian international advocate for clinical trials. She contributes to and is a pivotal member on many Australian and international clinical trial advocacy, policy and neurology focused leadership groups.

Over the past 7 years, Soulis has built up Neuroscience Trials Australia, a leading global specialised brand making Australia a destination for many overseas companies wanting to undertake neurology focused clinical research. This contract research organisation (CRO) is globally unique and offers clients access to clinical trial sites, expertise and capabilities required to complete clinical development at global standard.


 

Brought to you by ADDF ACCESS, a program of the ADDF and Science Exchange, as part of our commitment to connect ADDF researchers with technologies that can help accelerate breakthrough discoveries.